Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,248Price:$13.07
-
Apr 19, 2024 (filed on Apr 22, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,080Price:$5.31
-
Apr 05, 2024 (filed on Apr 08, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:32,697Price:$0.50
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Wright TimothyOwnership Type:Direct OwnershipSecurities:Deferred Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,135Price:--
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Hirsch Susan BOwnership Type:Direct OwnershipSecurities:Deferred Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:32,039Price:--
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Wiinberg UlfOwnership Type:Direct OwnershipSecurities:Deferred Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:38,635Price:--
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,163Price:$0.55
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,136Price:$0.67
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:21,815Price:$0.68
-
Feb 15, 2024 (filed on Feb 15, 2024)Insider Name:Armen Garo HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.65
Filings by filing date
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,248Price:$13.07
-
Feb 05, 2024 (filed on Apr 22, 2024)Insider Name:Hirsch Susan BOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,000Price:--
-
Feb 05, 2024 (filed on Apr 22, 2024)Insider Name:Jeynes-Ellis Allison MOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,000Price:--
-
Feb 05, 2024 (filed on Apr 22, 2024)Insider Name:Wright TimothyOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:7,500Price:--
-
Feb 05, 2024 (filed on Apr 22, 2024)Insider Name:Wiinberg UlfOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,000Price:--
-
Feb 05, 2024 (filed on Apr 22, 2024)Insider Name:Corvese BrianOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
-
Apr 19, 2024 (filed on Apr 22, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,080Price:$5.31
-
Apr 05, 2024 (filed on Apr 08, 2024)Insider Name:Armen Garo HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:32,697Price:$0.50
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Wright TimothyOwnership Type:Direct OwnershipSecurities:Deferred Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,135Price:--
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Hirsch Susan BOwnership Type:Direct OwnershipSecurities:Deferred Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:32,039Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3 Forbes Rd LEXINGTON MA 02421-7305 |
Tel: | N/A |
Website: | https://agenusbio.com |
IR: | See website |
Key People | ||
Garo H. Armen Chairman of the Board, Chief Executive Officer, Co-Founder | Christine M. Klaskin Vice President - Finance | Manuel Duenas Head of Market Access |
Stephanie Fagan Chief Communications Officer | Benny Johnson Senior Medical Director | Steven O'Day Chief Medical Officer |
Robin G. Taylor Chief Commercial Officer | Homa Yeganegi Chief Product Strategy and Global Medical Affairs Officer |
Business Overview |
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents. |
Financial Overview |
For the fiscal year ended 31 December 2023, Agenus Inc revenues increased 59% to $156.3M. Net loss applicable to common stockholders increased 12% to $246M. Revenues reflect United States segment increase of 75% to $153.3M. Higher net loss reflects R & D expenses increase of 26% to $228.3M (expense), Interest expense, net - Balancing value increase of 51% to $92.9M (expense). |
Employees: | 389 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $199.49M as of Dec 31, 2023 |
Annual revenue (TTM): | $156.31M as of Dec 31, 2023 |
EBITDA (TTM): | -$146.52M as of Dec 31, 2023 |
Net annual income (TTM): | -$245.97M as of Dec 31, 2023 |
Free cash flow (TTM): | -$234.16M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 20,284,748 as of Apr 17, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |